|
000
| 01766cam 2200301za 4500 |
|---|
| 001 | 9.856574 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107155550 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 180515s2018 oncd ob f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aYN5-156/2018E-PDF |
|---|
| 245 | 00|aPatent restoration and the cost of pharmaceuticals |h[electronic resource]. |
|---|
| 260 | |aOttawa : |bOffice of the Parliamentary Budget Officer, |c2018. |
|---|
| 300 | |a41 p. : |bcol. charts |
|---|
| 500 | |aIssued also in French under title: La prolongation de la durée des brevets et le coût des médicaments. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"26 April 2018." |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | 0 |a"This report estimates additional drug costs to Canadian consumers from changes to the Patent Law as negotiated under the Canada-European Union Comprehensive Economic and Trade Agreement (CETA). A two-year certificate of supplementary protection (CSP; elsewhere termed patent restoration, and used synonymously here since CSP provides patent-like protection) will delay the introduction of generic alternatives, and likely keep prices higher than they otherwise would be. The report also estimates the fiscal cost to the federal government of compensating provinces for increased costs to provincial public drug programs”--Verso of cover. |
|---|
| 693 | 4|aDrugs |
|---|
| 693 | 4|aPrices |
|---|
| 693 | 4|aPatent extensions |
|---|
| 693 | 4|aGovernment policy |
|---|
| 710 | 1 |aCanada. |bOffice of the Parliamentary Budget Officer. |
|---|
| 775 | 08|tLa prolongation de la durée des brevets et le coût des médicaments |w(CaOODSP)9.856575 |
|---|
| 856 | 40|qPDF|s606 KB|uhttps://publications.gc.ca/collections/collection_2018/dpb-pbo/YN5-156-2018-eng.pdf |
|---|